Innate Pharma Announces the Progression of the Clinical Trial Evaluating NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi to Phase 2 in Various Blood Cancers
Tuesday, April 16, 2024
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announces that the first patient has been treated in the Phase 2 dose expansion study ( NCT05086315 ). , led by Sanofi, evaluating SAR443579/IPH6101 as a monotherapy for the treatment of hematologic cancers with unmet medical need, including relapsed/refractory acute myelogenous leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplastic syndrome.
SAR443579, a trifunctional NK Cell Engager targeting CD123 and co-engaging NKp46 and CD16 receptors, is from a collaboration between Innate Pharma and Sanofi. SAR443579 has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. The efficacy and safety results from the dose escalation portion of the trial were presented in a poster at the American Society of Hematology 2 (ASH) 2023 Annual Meeting in San Diego (United States).
“ The progression of SAR443579 to the Phase 2 dose expansion trial in various blood cancers is a new step towards bringing this innovative NK cell engage to patients, ” commented Dr. Sonia Quaratino, Medical Director from Innate Pharma . “ SAR443579 showed promising clinical efficacy in the dose escalation portion of the Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia, and we look forward to seeing how the study progresses. dose expansion portion of the study. »
Under the terms of the 2016 research and licensing agreement with Sanofi , progression to the dose expansion portion of the trial triggered a milestone payment to Innate of €4 million.
“ Our goal is to continue to develop the best and most effective treatments for cancer patients,” said Peter Adamson, Director of Oncology Development, Sanofi . “We are buoyed by the progress made in this study for patients with acute myeloid leukemia, and we look forward to sharing future results as the data emerge. »
More information about the Phase 1/2 trial is available at clinicaltrials.gov .
About ANKET ® :
ANKET ® ( A ntibody-based NK cell Engager Therapeutics ) is Innate Pharma's proprietary platform enabling the development of a new generation of multi-specific NK cell engagers to treat certain types of cancer .
This versatile technology makes it possible to create an entire new class of molecules inducing synthetic immunity against cancer.
About the Sanofi/Innate collaboration and licensing agreement:
Innate has a collaboration and licensing agreement with Sanofi to apply Innate's proprietary technology to the development of multi-specific antibodies that engage NK cells via the activating receptors NKp46 and CD16 to eliminate tumor cells.
Under the terms of the 2016 collaboration and licensing agreement , Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the collaboration, which includes SAR443579/IPH6101 (targeting CD123) and SAR445514/IPH6401 (targeting BCMA). Innate Pharma is eligible for milestone payments linked to the achievement of development and marketing objectives of up to €400 million as well as royalties based on net sales.
Under the terms of the collaboration and licensing agreement concluded in December 2022, which includes IPH62 (targeting B7-H3), IPH67 and an option on an additional target, Innate is eligible for up to €1.35 billion in payment of milestones linked to the achievement of preclinical, clinical, regulatory and commercial objectives as well as royalties on potential net sales.
About Innate Pharma:
Innate Pharma SA is a clinical-stage biotechnology company developing immunotherapy treatments against cancer. Its innovative approach aims to take advantage of the innate immune system through therapeutic antibodies and its proprietary ANKET ® ( A ntibody-based NK cell Engager Therapeutics ) platform.
Innate's portfolio includes the proprietary lacutamab program, developed in advanced forms of cutaneous T-cell lymphomas and peripheral T-cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as multi-specific antibodies involving NK cells from its ANKET ® platform which can target different types of cancers.
To accelerate innovation, research and development of treatments to benefit patients, Innate Pharma is a trusted partner for leading biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions.
Based in Marseille, with a subsidiary in Rockville (Maryland, United States), Innate Pharma is listed on the Euronext Paris stock exchange and on the Nasdaq in the United States.
Find Innate Pharma on www.innate-pharma.com and follow our news on X and LinkedIn .
Useful information :
ISIN code: FR0010331421
Mnemonic code: Euronext: IPH Nasdaq: IPHA
LEI: 9695002Y8420ZB8HJE29
Disclaimer regarding forward-looking information and risk factors:
This press release contains forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain terms, including "believe", "potential", "expect" and "will" and other similar expressions, are intended to identify forward-looking statements. Although the Company considers that its projections are based on reasonable assumptions, these forward-looking statements may be affected by a number of hazards and uncertainties, which could result in results materially different from those anticipated. These risks and uncertainties include in particular the uncertainties inherent in research and development, including those relating to safety, progress and results of ongoing or planned clinical trials and preclinical studies, reviews and authorizations from regulatory authorities concerning the Company's product candidates, the Company's commercial efforts, the Company's ability to continue to raise funds for its development. For additional considerations regarding risks and uncertainties that could cause the actual results, financial position, performance and achievements of the Company to differ, please refer to the “Risk Factors” section of the Universal Registration Document filed with the Financial Markets Authority (AMF), available on the websites of Innate Pharma ( www.innate-pharma.com ) and the AMF ( www.amf-france.org ), and the documents and public reports filed with the United States Securities and Exchange Commission (SEC), including the annual report on “Form 20-F” for the fiscal year ended December 31, 2023 and subsequent documents and reports filed with the AMF or the SEC, or otherwise made public, by the Company.
This press release, and the information it contains, constitute neither an offer to sell or subscribe, nor the solicitation of an order to purchase or subscribe, for Innate Pharma shares in any country.
1 American Medicines Agency
2 American Society of Hematology
Contacts
Investor Relations and Media
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
henry.wheeler@innate-pharma.fr
NewCap
Arthur Rouille
Tel. : +33 (0)1 44 71 00 15
innate@newcap.eu
Source: businesswire.com
